Mieke Van Hemelrijck

List of Publications by Year
in descending order

325 papers	7,688 citations	50170 46 h-index	85405 71 g-index
334 all docs	334 docs citations	334 times ranked	12519 citing authors

#	Article	IF	Citations
1	Phase III study of the European Organisation for Research and Treatment of Cancer Quality of Life cancer survivorship core questionnaire. Journal of Cancer Survivorship, 2023, 17, 1111-1130.	1.5	6
2	Developing a consensus statement for psychosocial support in active surveillance for prostate cancer. BJUI Compass, 2023, 4, 104-113.	0.7	1
3	Supportive care needs and utilization of bladder cancer patients undergoing radical cystectomy: A longitudinal study. Psycho-Oncology, 2022, 31, 219-226.	1.0	8
4	Time-Dependent COVID-19 Mortality in Patients With Cancer. JAMA Oncology, 2022, 8, 114.	3.4	50
5	Effect of Simulation-based Training on Surgical Proficiency and Patient Outcomes: A Randomised Controlled Clinical and Educational Trial. European Urology, 2022, 81, 385-393.	0.9	21
6	Risk of bladder cancer death in patients younger than 50 with non-muscle-invasive and muscle-invasive bladder cancer. Scandinavian Journal of Urology, 2022, 56, 27-33.	0.6	5
7	Standardising the Assessment of Patient-reported Outcome Measures in Localised Prostate Cancer. A Systematic Review. European Urology Oncology, 2022, 5, 153-163.	2.6	15
8	The Impact of COVID-19 on the Delivery of Systemic Anti-Cancer Treatment at Guyâ€™s Cancer Centre. Cancers, 2022, 14, 266.	1.7	2
9	Association between COVID-19 burden and delays to diagnosis and treatment of cancer patients in England. Journal of Cancer Policy, 2022, 31, 100316.	0.6	9
10	Hormonal patterns in men with prediabetes and diabetes in NHANES III: possible links with prostate cancer. Cancer Causes and Control, 2022, 33, 429-440.	0.8	3
11	Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundationâ€™s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. European Urology Open Science, 2022, 35, 59-67.	0.2	13
12	The impact of hospital attendance on COVID-19 infection in cancer patients: an assessment of data from Guy's Cancer. Future Oncology, 2022, 18, 1211-1218.	1.1	4
13	Exercise prehabilitation during neoadjuvant chemotherapy may enhance tumour regression in oesophageal cancer: results from a prospective non-randomised trial. British Journal of Sports Medicine, 2022, 56, 402-409.	3.1	25
14	Evaluating the performance of temporal pattern discovery: new application using statins and rhabdomyolysis in OMOP databases. BMC Medical Informatics and Decision Making, 2022, 22, 31.	1.5	3
15	Effect of peri-operative chemotherapy regimen on survival in the treatment of locally advanced oesophago-gastric adenocarcinoma â€“ A comparison of the FLOT and â€˜MAGICâ€™ regimens. European Journal of Cancer, 2022, 163, 180-188.	1.3	8
16	Population-based estimates of age and comorbidity specific life expectancy: a first application in Swedish males. BMC Medical Informatics and Decision Making, 2022, 22, 35.	1.5	8
17	Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium. European Urology, 2022, 81, 503-514.	0.9	13
18	COVID-19 vaccination in patients with cancer, a rapid review. Ecancermedicalscience, 2022, 16, 1355.	0.6	4

#	Article	IF	Citations
19	Mortality Among Adults With Cancer Undergoing Chemotherapy or Immunotherapy and Infected With COVID-19. JAMA Network Open, 2022, 5, e220130.	2.8	34
20	An exploration of wellbeing in men diagnosed with prostate cancer undergoing active surveillance: a qualitative study. Supportive Care in Cancer, 2022, 30, 5459-5468.	1.0	4
21	Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database. Prostate, 2022, 82, 876-879.	1.2	2
22	Scoping review: bladder cancer in Nigeria â€“ what are the gaps in clinical care and research?. BMJ Open, 2022, 12, e049241.	0.8	0
23	Antibodies as biomarkers for cancer risk: a systematic review. Clinical and Experimental Immunology, 2022, 209, 46-63.	1.1	13
24	Cancer staff in an NHS cancer center: infections, vaccination, stress and well-being support during the COVID-19 pandemic. Future Oncology, 2022, , .	1.1	0
25	Diagnostic and prognostic factors in patients with prostate cancer: a systematic review. BMJ Open, 2022, 12, e058267.	0.8	4
26	Qualitative Analysis of Interviews and Focus Groups Exploring Factors Contributing to Adherence to GnRH Agonists in Men with Prostate Cancer. Seminars in Oncology Nursing, 2022, 38, 151236.	0.7	2
27	COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry. Journal of the National Cancer Institute, 2022, 114, 979-987.	3.0	14
28	Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry. European Journal of Cancer, 2022, 170, 10-16.	1.3	11
29	Safe provision of systemic anti-cancer treatment for urological cancer patients during COVID-19: a tertiary centre experience in the first wave of COVID-19. BMC Urology, 2022, 22, 71.	0.6	0
30	Secondary Treatment for Men with Localized Prostate Cancer: A Pooled Analysis of PRIAS and ERSPC-Rotterdam Data within the PIONEER Data Platform. Journal of Personalized Medicine, 2022, 12, 751.	1.1	0
31	Clinical assessment of the Omicron outbreak in Europe and trends in morbidity and mortality from COVID-19 and cancer.. Journal of Clinical Oncology, 2022, 40, e18673-e18673.	0.8	1
32	Negative first followâ€up prostate biopsy on active surveillance is associated with decreased risk of upgrading, suspicion of progression and converting to active treatment. BJU International, 2021, 128, 72-78.	1.3	3
33	Effect of a brief physical activity-based presentation by a former patient for men treated with radical prostatectomy for prostate cancer: a mixed methods pilot study. Supportive Care in Cancer, 2021, 29, 145-154.	1.0	3
34	Personalised biopsy schedules based on risk of Gleason upgrading for patients with lowâ€risk prostate cancer on active surveillance. BJU International, 2021, 127, 96-107.	1.3	15
35	Depression, anxiety, and suicidality in patients with prostate cancer: a systematic review and meta-analysis of observational studies. Prostate Cancer and Prostatic Diseases, 2021, 24, 281-289.	2.0	50
36	Development of a preâ€and postoperative physical activity promotion program integrated in the electronic health system of patients with bladder cancer (The POPEYE study): An intervention mapping approach. European Journal of Cancer Care, 2021, 30, e13363.	0.7	4

#	Article	IF	Citations
37	Risk of cardiovascular disease following gonadotropinâ€releasing hormone agonists vs antagonists in prostate cancer: Realâ€world evidence from five databases. International Journal of Cancer, 2021, 148, 2203-2211.	2.3	19
38	How does COVIDâ€19 impact treatment decisionâ€making for clinicians in localised kidney cancer. BJUI Compass, 2021, 2, 11-12.	0.7	2
39	The experience of UK patients with bladder cancer during the COVIDâ€19 pandemic: a surveyâ€based snapshot. BJU International, 2021, 127, 179-181.	1.3	5
40	Metabolic syndrome biomarkers and prostate cancer risk in the <scp>UK</scp> Biobank. International Journal of Cancer, 2021, 148, 825-834.	2.3	20
41	Systematic review of the association between socioeconomic status and bladder cancer survival with hospital type, comorbidities, and treatment delay as mediators. BJUI Compass, 2021, 2, 140-158.	0.7	6
42	Scoping review protocol: bladder cancer in Nigeria: what are the gaps in clinical care and research?. BMJ Open, 2021, 11, e041894.	0.8	5
43	The effectiveness of the Guyâ€™s Rapid Diagnostic Clinic (RDC) in detecting cancer and serious conditions in vague symptom patients. British Journal of Cancer, 2021, 124, 1079-1087.	2.9	21
44	Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110422.	1.4	4
45	Gender Differences in Concerns About Participating in Cancer Research During the COVID-19 Pandemic. Cancer Control, 2021, 28, 107327482198931.	0.7	7
46	Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients. Cancer Cell, 2021, 39, 257-275.e6.	7.7	93
47	Presentation, follow-up, and outcomes among African/Afro-Caribbean men on active surveillance for prostate cancer: experiences of a high-volume UK centre. Prostate Cancer and Prostatic Diseases, 2021, 24, 549-557.	2.0	1
48	Adjuvant therapy following neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma in patients with clear resection margins. Acta OncolÃ³gica, 2021, 60, 672-680.	0.8	3
49	Risk of cardiovascular events in men on abiraterone or enzalutamide combined with GnRH agonists: nation-wide, population-based cohort study in Sweden. Acta OncolÃ³gica, 2021, 60, 459-465.	0.8	7
50	Diagnostic and prognostic factors in patients with prostate cancer: a systematic review protocol. BMJ Open, 2021, 11, e040531.	0.8	4
51	A first step towards a global nomogram to predict disease progression for men on active surveillance. Translational Andrology and Urology, 2021, 10, 1102-1109.	0.6	0
52	Continuity of Cancer Care: The Surgical Experience of Two Large Cancer Hubs in London and Milan. Cancers, 2021, 13, 1597.	1.7	17
53	Is there a role for physical activity interventions in the treatment pathway of bladder cancer? A scoping review of the literature. BMJ Open Sport and Exercise Medicine, 2021, 7, e000951.	1.4	4
54	Pancreatic Cancer Exposome Profile to Aid Early Detection and Inform Prevention Strategies. Journal of Clinical Medicine, 2021, 10, 1665.	1.0	5

#	Article	IF	Citations
55	Cancer and COVID-19 vaccines: a complex global picture. Lancet Oncology, The, 2021, 22, 749-751.	5.1	20
56	Outcomes of head and neck cancer management from two cancer centres in Southern and Northern Europe during the first wave of COVID-19. Tumori, 2021, , 030089162110079.	0.6	3
57	Guyâ€™s and St Thomas NHS Foundation active surveillance prostate cancer cohort: a characterisation of a prostate cancer active surveillance database. BMC Cancer, 2021, 21, 573.	1.1	2
58	COVID-19 Risk Factors for Cancer Patients: A First Report with Comparator Data from COVID-19 Negative Cancer Patients. Cancers, 2021, 13, 2479.	1.7	13
59	Update from the RelMAGINE Prostate Cancer Screening Study NCT04063566: Inviting Men for Prostate Cancer Screening Using Magnetic Resonance Imaging. European Urology Focus, 2021, 7, 503-505.	1.6	5
60	Factors that influence patientsâ€™ views on treatment decision-making in localised kidney cancer. Translational Andrology and Urology, 2021, 10, 2824-2827.	0.6	1
61	Survival Outcomes in Invasive Lobular Carcinoma Compared to Oestrogen Receptor-Positive Invasive Ductal Carcinoma. Cancers, 2021, 13, 3036.	1.7	7
62	Expectant management in genitourinary malignancies (prostate, bladder, kidney). Translational Andrology and Urology, 2021, 10, 2715-2718.	0.6	0
63	Using the Movember Foundationâ€™s GAP3 cohort to measure the effect of active surveillance on patient-reported urinary and sexual functionâ€”a retrospective study in low-risk prostate cancer patients. Translational Andrology and Urology, 2021, 10, 2719-2727.	0.6	4
64	The need for research methodology to improve acceptability of long-term surveillance for cancer. Translational Andrology and Urology, 2021, 10, 2820-2823.	0.6	1
65	Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study. European Journal of Cancer, 2021, 150, 190-202.	1.3	37
66	Understanding reasons for non-adherence to active surveillance for low-intermediate risk prostate cancer. Translational Andrology and Urology, 2021, 10, 2728-2736.	0.6	10
67	Tumor-Infiltrating B Lymphocyte Profiling Identifies IgG-Biased, Clonally Expanded Prognostic Phenotypes in Triple-Negative Breast Cancer. Cancer Research, 2021, 81, 4290-4304.	0.4	40
68	Risk-Based Selection for Active Surveillance: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Initiative. Journal of Urology, 2021, 206, 62-68.	0.2	6
69	Global cancer research in the era of COVID-19: a bibliometric analysis. Ecancermedicalscience, 2021, 15, 1264.	0.6	12
70	A meta-analysis of the efficacy of vascularised lymph node transfer in reducing limb volume and cellulitis episodes in patients with cancer treatment-related lymphoedema. European Journal of Cancer, 2021, 151, 233-244.	1.3	12
71	COVID-19 Vaccine Safety in Cancer Patients: A Single Centre Experience. Cancers, 2021, 13, 3573.	1.7	39
72	Erectile Function Following Surgery for Benign Prostatic Obstruction: A Systematic Review and Network Meta-analysis of Randomised Controlled Trials. European Urology, 2021, 80, 174-187.	0.9	5

#	Article	IF	Citations
73	The incidence and prevalence of upper tract urothelial carcinoma: a systematic review. BMC Urology, 2021, 21, 110.	0.6	28
74	Risk of COVID-19 death in cancer patients: an analysis from Guyâ€™s Cancer Centre and Kingâ€™s College Hospital in London. British Journal of Cancer, 2021, 125, 939-947.	2.9	41
75	Providing a Framework for Meaningful Patient Involvement in Clinical Practice Guideline Development and Implementation. European Urology Focus, 2021, 7, 947-950.	1.6	8
76	Association between serum markers of the humoral immune system and inflammation in the Swedish AMORIS study. BMC Immunology, 2021, 22, 61.	0.9	7
77	646 PREDICTING RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH OESOPHAGEAL ADENOCARCINOMA. Ecological Management and Restoration, 2021, 34, .	0.2	0
78	ReIMAGINE Prostate Cancer Screening Study: protocol for a single-centre feasibility study inviting men for prostate cancer screening using MRI. BMJ Open, 2021, 11, e048144.	0.8	10
79	Validation and reliability of the Dutch version of the EORTC QLQ-NMIBC24 Questionnaire Module for patients with non-muscle-invasive bladder cancer. Journal of Patient-Reported Outcomes, 2021, 5, 96.	0.9	5
80	Circulating Tumour Cell Numbers Correlate with Platelet Count and Circulating Lymphocyte Subsets in Men with Advanced Prostate Cancer: Data from the ExPeCT Clinical Trial (CTRIAL-IE 15-21). Cancers, 2021, 13, 4690.	1.7	11
81	The Current Evidence for Factors that Influence Treatment Decision Making in Localized Kidney Cancer: A Mixed Methods Systematic Review. Journal of Urology, 2021, 206, 827-839.	0.2	5
82	The Key Role of Patient Involvement in the Development of Core Outcome Sets in Prostate Cancer. European Urology Focus, 2021, 7, 943-946.	1.6	6
83	Reply by Authors. Journal of Urology, 2021, 206, 839-839.	0.2	0
84	The importance of patient and public involvement in cancer research: time to create a new job profile. Future Oncology, 2021, 17, 3667-3670.	1.1	3
85	The need for supportive mental wellbeing interventions in bladder cancer patients: A systematic review of the literature. PLoS ONE, 2021, 16, e0243136.	1.1	5
86	An assessment of the use of patient reported outcome measurements (PROMs) in cancers of the pelvic abdominal cavity: identifying oncologic benefit and an evidence-practice gap in routine clinical practice. Health and Quality of Life Outcomes, 2021, 19, 20.	1.0	8
87	Designing a Pragmatic Intervention to Help Improve the Bladder Cancer Patient Experience. Inquiry (United States), 2021, 58, 004695802110302.	0.5	2
88	Is there a role for physical activity when treating patients with cancer with immune checkpoint inhibitors? Protocol for a scoping review. BMJ Open, 2021, 11, e046052.	0.8	1
89	Predicting response to neoadjuvant chemotherapy in patients with oesophageal adenocarcinoma. Acta OncolÃ³gica, 2021, 60, 1629-1636.	0.8	2
90	â€œSomething Good Has to Come Out of the Horrorâ€¦ A Qualitative Examination of Cancer Survivors' Attitudes Towards Participation in Research During the First Year of the COVID-19 Pandemic. Frontiers in Public Health, 2021, 9, 741188.	1.3	1

#	Article	IF	Citations
91	Comparison of Characteristics, Follow-up and Outcomes of Active Surveillance for Prostate Cancer According to Ethnicity in the GAP3 Global Consortium Database. European Urology Open Science, 2021, 34, 47-54.	0.2	3
92	Supportive Roles of the Health Care Team Throughout the Illness Trajectory of Bladder Cancer Patients Undergoing Radical Cystectomy: A Qualitative Study Exploring the Patientsâ€™ Perspectives. Seminars in Oncology Nursing, 2021, 37, 151226.	0.7	4
93	Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. Lancet Oncology, The, 2021, 22, 1669-1680.	5.1	73
94	Serum Total Bilirubin and Risk of Cancer: A Swedish Cohort Study and Meta-Analysis. Cancers, 2021, 13, 5540.	1.7	10
95	Impact of the COVID-19 Pandemic on Cancer Researchers in 2020: A Qualitative Study of Events to Inform Mitigation Strategies. Frontiers in Public Health, 2021, 9, 741223.	1.3	7
96	Exploring the association between use of gonadotropin releasing hormones agonists and prostate cancer diagnosis per se and diabetes control in men with type 2 diabetes mellitus: a nationwide, population-based cohort study. BMC Cancer, 2021, 21, 1259.	1.1	1
97	The RelMAGINE Multimodal Warehouse: Using Artificial Intelligence for Accurate Risk Stratification of Prostate Cancer. Frontiers in Artificial Intelligence, 2021, 4, 769582.	2.0	2
98	Independent Prognostic Value of Flow Cytometry (FCM) in Myelodysplastic Syndromes (MDS) - Composition of a Prognostic FCM-Score for Overall Survival. Blood, 2021, 138, 2603-2603.	0.6	0
99	RelMAGINE: a prostate cancer research consortium with added value through its patient and public involvement and engagement. Research Involvement and Engagement, 2021, 7, 81.	1.1	3
100	Global cancer research in the post-pandemic world. Lancet Oncology, The, 2021, 22, 1652-1654.	5.1	11
101	COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110534.	1.4	5
102	Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundationâ€™s Global Action Plan Prostate Cancer Active Surveillance Initiative. European Urology Oncology, 2020, 3, 80-91.	2.6	24
103	Long-term adherence to GnRH agonists in men with prostate cancer. A nation-wide population-based study in prostate cancer data base Sweden. Scandinavian Journal of Urology, 2020, 54, 20-26.	0.6	11
104	A Systematic Review and Meta-analysis of Delay in Radical Cystectomy and the Effect on Survival in Bladder Cancer Patients. European Urology Oncology, 2020, 3, 239-249.	2.6	67
105	Long-term Oncological Outcomes from an Early Phase Randomised Controlled Three-arm Trial of Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL). European Urology, 2020, 77, 110-118.	0.9	82
106	Editorial: Bladder Cancer â€“ A Cinderella Cancer: Advances and Remaining Research Questions. Frontiers in Oncology, 2020, 10, 1749.	1.3	2
107	PIONEERâ€™s systematic review of outcomes in RCTs of men with non-metastatic castration resistant prostate cancer: Is there a need for a core outcome set?. European Urology Open Science, 2020, 19, e1795.	0.2	1
108	Exploring a role for fatty acid synthase in prostate cancer cell migration. Small GTPases, 2020, 12, 1-8.	0.7	7

#	Article	IF	Citations
109	Feasibility study to identify women of childbearing age at risk of pregnancy not using any contraception in The Health Improvement Network (THIN) database. BMC Medical Informatics and Decision Making, 2020, 20, 164.	1.5	2
110	Association Between Vitamin D and Novel SARS-CoV-2 Respiratory Dysfunction â€“ A Scoping Review of Current Evidence and Its Implication for COVID-19 Pandemic. Frontiers in Physiology, 2020, 11, 564387.	1.3	27
111	Impact of age on the toxicity of immune checkpoint inhibition. , 2020, 8, e000871.		37
112	Factors Affecting COVID-19 Outcomes in Cancer Patients: A First Report From Guy's Cancer Center in London. Frontiers in Oncology, 2020, 10, 1279.	1.3	49
113	Investigating the impact of open label design on patientâ€reported outcome results in prostate cancer randomized controlled trials. Cancer Medicine, 2020, 9, 7363-7374.	1.3	19
114	A mediation analysis to explain socioâ€economic differences in bladder cancer survival. Cancer Medicine, 2020, 9, 7477-7487.	1.3	10
115	One Piece of the Jigsaw for the Cancer Recovery Strategy: Prevalence of COVID-19 in Patients With Cancer. Cancer Control, 2020, 27, 107327482095084.	0.7	8
116	Examination of potential novel biochemical factors in relation to prostate cancer incidence and mortality in UK Biobank. British Journal of Cancer, 2020, 123, 1808-1817.	2.9	15
117	Cohort profile: Kingâ€™s Health Partners bladder cancer biobank. BMC Cancer, 2020, 20, 920.	1.1	0
118	Use of Warfarin or Direct Oral Anticoagulants and Risk of Prostate Cancer in PCBaSe: A Nationwide Case-Control Study. Frontiers in Oncology, 2020, 10, 571838.	1.3	4
119	Introducing PIONEER: a project to harness big data in prostate cancer research. Nature Reviews Urology, 2020, 17, 351-362.	1.9	18
120	Unmet needs in sexual health in bladder cancer patients: a systematic review of the evidence. BMC Urology, 2020, 20, 64.	0.6	22
121	Health-related quality of life overview after different curative treatment options in muscle-invasive bladder cancer: an umbrella review. Quality of Life Research, 2020, 29, 2887-2910.	1.5	14
122	Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer: a population-based case-control study. BMC Cancer, 2020, 20, 551.	1.1	10
123	Guyâ€™s cancer cohort â€“ real world evidence for cancer pathways. BMC Cancer, 2020, 20, 187.	1.1	13
124	Association of Serum Immunoglobulin Levels with Solid Cancer: A Systematic Review and Meta-analysis. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 527-538.	1.1	13
125	Serum Immunoglobulin G Is Associated With Decreased Risk of Pancreatic Cancer in the Swedish AMORIS Study. Frontiers in Oncology, 2020, 10, 263.	1.3	7
126	Overall survival, diseaseâ€specific survival and local recurrence outcomes in patients with muscleâ€invasive bladder cancer treated with external beam radiotherapy and brachytherapy: a systematic review. BJU International, 2020, 125, 780-791.	1.3	6

#	Article	IF	Citations
127	Lipogenic signalling modulates prostate cancer cell adhesion and migration via modification of Rho GTPases. Oncogene, 2020, 39, 3666-3679.	2.6	35
128	Simulation in Urological Training and Education (SIMULATE): Protocol and curriculum development of the firstÂmulticentre international randomized controlled trial assessing the transferability of simulationâ€based surgicalÂtraining. BJU International, 2020, 126, 202-211.	1.3	18
129	Spironolactone use is associated with lower prostate cancer risk: a population-wide case-control study. Prostate Cancer and Prostatic Diseases, 2020, 23, 527-533.	2.0	14
130	Harnessing the patient voice in prostate cancer research: Systematic review on the use of patientâ€reported outcomes in randomized controlled trials to support clinical decisionâ€making. Cancer Medicine, 2020, 9, 4039-4058.	1.3	11
131	Platelet cloaking of circulating tumour cells in patients with metastatic prostate cancer: Results from ExPeCT, a randomised controlled trial. PLoS ONE, 2020, 15, e0243928.	1.1	13
132	Associations between immune-suppressive and stimulating drugs and novel COVID-19â€"a systematic review of current evidence. Ecancermedicalscience, 2020, 14, 1022.	0.6	360
133	COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?. Ecancermedicalscience, 2020, 14, 1023.	0.6	235
134	Anosmia and ageusia are emerging as symptoms in patients with COVID-19: What does the current evidence say?. Ecancermedicalscience, 2020, 14, ed98.	0.6	88
135	LBA01-05â€ƒSIMULATION IN UROLOGICAL TRAINING AND EDUCATION (SIMULATE): AN INTERNATIONAL RANDOMISED CONTROLLED CLINICAL AND EDUCATIONAL TRIAL TO DETERMINE THE EFFECT OF SIMULATION-BASED SURGICAL TRAINING. Journal of Urology, 2020, 203, .	0.2	0
136	PD62-01â€ƒA FIRST STEP TOWARDS A GLOBAL NOMOGRAM TO PREDICT DISEASE PROGRESSION FOR MEN ON ACTIVE SURVEILLANCE. Journal of Urology, 2020, 203, e1285.	0.2	0
137	PD62-11â€ƒPATIENT-REPORTED ERECTILE AND URINARY FUNCTION AFTER REPEAT BIOPSIES IN MEN ON ACTIVE SURVEILLANCE. RESULTS OF THE MOVEMBER FOUNDATIONâ€™S GAP3 COHORT. Journal of Urology, 2020, 203, .	0.2	0
138	The success of the Rapid Diagnostic Clinic (RDC) detecting new cancers in patients with non-localizing symptoms.. Journal of Clinical Oncology, 2020, 38, 303-303.	0.8	0
139	Disparities in COVID-19 severity and risk of death in cancer patients: Experiences from a U.K. cancer center.. Journal of Clinical Oncology, 2020, 38, 285-285.	0.8	0
140	C-CRES: COVID-19 and cancer research engagement study.. Journal of Clinical Oncology, 2020, 38, 182-182.	0.8	2
141	Adjuvant therapy following oesophagectomy for adenocarcinoma in patients with a positive resection margin. British Journal of Surgery, 2020, 107, 1801-1810.	0.1	3
142	Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?. BMC Urology, 2019, 19, 73.	0.6	0
143	Reply to Jon Mikel Inarritu, Daniele Castellani, and Jeremy Y.C. Teoh's Letter to the Editor re: Agustina Bessa, Steven Maclennan, Deborah Enting, et al. Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi Method. Eur Urol 2019;76:260â€"1. European Urology, 2019, 76, e45-e46.	0.9	1
144	Metabolic profiles to predict long-term cancer and mortality: the use of latent class analysis. BMC Molecular and Cell Biology, 2019, 20, 28.	1.0	4

#	Article	IF	Citations
145	The global prevalence of erectile dysfunction: a review. BJU International, 2019, 124, 587-599.	1.3	170
146	Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy Results. JAMA Network Open, 2019, 2, e1914689.	2.8	16
147	Barriers and facilitators to physical activity in men with prostate cancer: A qualitative and quantitative systematic review. Psycho-Oncology, 2019, 28, 2270-2285.	1.0	35
148	Serum immunoglobulin levels and the risk of bladder cancer in the AMORIS Cohort. Cancer Epidemiology, 2019, 62, 101584.	0.8	4
149	Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts. European Urology, 2019, 76, 693-702.	0.9	18
150	Chronic inflammation markers are associated with risk of pancreatic cancer in the Swedish AMORIS cohort study. BMC Cancer, 2019, 19, 858.	1.1	30
151	Patient-reported outcomes in randomised clinical trials of bladder cancer: an updated systematic review. BMC Urology, 2019, 19, 86.	0.6	10
152	Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi Method. European Urology, 2019, 76, 258-259.	0.9	30
153	Chronic inflammatory diseases, anti-inflammatory medications and risk of prostate cancer: a population-based case-control study. BMC Cancer, 2019, 19, 612.	1.1	9
154	How to measure temporal changes in care pathways for chronic diseases using health care registry data. BMC Medical Informatics and Decision Making, 2019, 19, 103.	1.5	3
155	Neoadjuvant chemotherapy for muscle invasive bladder cancer: a nationwide investigation on survival. Scandinavian Journal of Urology, 2019, 53, 206-212.	0.6	8
156	Immune mediator expression signatures are associated with improved outcome in ovarian carcinoma. OncoImmunology, 2019, 8, e1593811.	2.1	20
157	Baseline serum folate, vitamin B12 and the risk of prostate and breast cancer using data from the Swedish AMORIS cohort. Cancer Causes and Control, 2019, 30, 603-615.	0.8	15
158	The burden of urological cancers in lowâ€•and middleâ€•income countries. BJU International, 2019, 123, 557-557.	1.3	2
159	Survival after radiotherapy versus radical cystectomy for primary muscleâ€•invasive bladder cancer: A Swedish nationwide populationâ€•based cohort study. Cancer Medicine, 2019, 8, 2196-2204.	1.3	12
160	Realâ€•world insights into risk of developing cardiovascular disease following Gn<scp>RH</scp> agonists versus antagonists for prostate cancer: a methodological protocol to a study using five European databases. Fundamental and Clinical Pharmacology, 2019, 33, 479-499.	1.0	3
161	PCASTt/SPCG-17â€”a randomised trial of active surveillance in prostate cancer: rationale and design. BMJ Open, 2019, 9, e027860.	0.8	19
162	Graham Roberts Study protocol: first â€˜trials within cohort studyâ€™ for bladder cancer. BMJ Open, 2019, 9, e029468.	0.8	7

#	Article	IF	Citations
163	Scoping review protocol: is there a role for physical activity interventions in the treatment pathway of bladder cancer?. BMJ Open, 2019, 9, e033518.	0.8	5
164	Prediction of a positive circumferential resection margin at surgery following neoadjuvant chemotherapy for adenocarcinoma of the oesophagus. BJS Open, 2019, 3, 767-776.	0.7	3
165	Serum IgG Is Associated With Risk of Melanoma in the Swedish AMORIS Study. Frontiers in Oncology, 2019, 9, 1095.	1.3	5
166	Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies. European Urology Oncology, 2019, 2, 333-336.	2.6	8
167	A Single Educational Seminar Increases Confidence and Decreases Dropout from Active Surveillance by 5 Years After Diagnosis of Prostate Cancer. European Urology Oncology, 2019, 2, 464-470.	2.6	8
168	Serum glucose, triglycerides, and cholesterol in relation to prostate cancer death in the Swedish AMORIS study. Cancer Causes and Control, 2019, 30, 195-206.	0.8	14
169	Androgen deprivation therapy for prostate cancer and risk of dementia. BJU International, 2019, 124, 87-92.	1.3	26
170	Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium. European Urology, 2019, 75, 523-531.	0.9	58
171	Anti-androgen monotherapy versus gonadotropin-releasing hormone agonists in men with advanced, non-metastatic prostate cancer: a register-based, observational study. Acta OncolÃ³gica, 2019, 58, 110-118.	0.8	4
172	Selenium and Sex Steroid Hormones in a U.S. Nationally Representative Sample of Men: A Role for the Link between Selenium and Estradiol in Prostate Carcinogenesis?. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 578-583.	1.1	3
173	Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer. European Urology, 2019, 75, 676-683.	0.9	12
174	The effect of a structured exercise intervention on CTCs and platelet cloaking in patients with metastatic prostate cancer.. Journal of Clinical Oncology, 2019, 37, 243-243.	0.8	2
175	MP22-11â€ƒCHANGES IN COMORBIDITY AFTER TREATMENT WITH GONADOTROPHIN RELEASING AGONISTS VERSUS ANTI-ANDROGEN MONOTHERAPY IN MEN WITH ADVANCED NON-METASTATIC PROSTATE CANCER. Journal of Urology, 2019, 201, .	0.2	0
176	MP48-07â€ƒTHIRTY-YEAR NATIONWIDE POPULATION-BASED FOLLOW-UP OF MEN ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER: WHO BENEFITS THE MOST? A STATE-TRANSITION ANALYSIS. Journal of Urology, 2019, 201, .	0.2	0
177	MP48-18â€ƒIS PSA â€˜SCREENINGâ€™ BEHAVIOUR ASSOCIATED WITH UPTAKE OF ACTIVE SURVEILLANCE IN MEN WITH LOW RISK PROSTATE CANCER?. Journal of Urology, 2019, 201, .	0.2	0
178	A randomized trial of exercise on quality of life in men with metastatic prostate cancer: The ExPeCT Trial.. Journal of Clinical Oncology, 2019, 37, 97-97.	0.8	9
179	Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of Cancer. Clinical Cancer Research, 2018, 24, 1617-1628.	3.2	44
180	The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date. BJU International, 2018, 121, 737-744.	1.3	51

#	Article	IF	Citations
181	Serum inflammatory markers in relation to prostate cancer severity and death in the Swedish AMORIS study. International Journal of Cancer, 2018, 142, 2254-2262.	2.3	40
182	A comparison of the left thoracoabdominal and Ivorâ€“Lewis esophagectomy. Ecological Management and Restoration, 2018, 31, .	0.2	10
183	Determinants of cancer screening awareness and participation among Indonesian women. BMC Cancer, 2018, 18, 208.	1.1	55
184	Factors Influencing Men's Choice of and Adherence to Active Surveillance for Low-risk Prostate Cancer: A Mixed-method Systematic Review. European Urology, 2018, 74, 261-280.	0.9	82
185	The risk of prostate cancer mortality and cardiovascular mortality of nonmetastatic prostate cancer patients: A population-based retrospective cohort study. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 309.e15-309.e23.	0.8	17
186	Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study. BMJ Open, 2018, 8, e020787.	0.8	8
187	Association between type 2 diabetes, curative treatment and survival in men with intermediateâ€•and highâ€•risk localized prostate cancer. BJU International, 2018, 121, 209-216.	1.3	4
188	Drugs for metabolic conditions and prostate cancer death in men on Gn<scp>RH</scp> agonists. BJU International, 2018, 121, 260-267.	1.3	3
189	Brief behavioural intervention, delivered as standard care, to support physical activity engagement in men with prostate cancer: a pilot study protocol. BMJ Open Sport and Exercise Medicine, 2018, 4, e000469.	1.4	2
190	The risk of cardiovascular disease following GnRH agonists versus antagonists: Real-world evidence from four European countries. European Urology Supplements, 2018, 17, e1850.	0.1	1
191	A systematic review of the literature exploring the interplay between prostate cancer and type two diabetes mellitus. Ecancermedicalscience, 2018, 12, 802.	0.6	19
192	Patients' perspectives on opt-out consent for observational research: systematic review and focus group. British Journal of Nursing, 2018, 27, 1321-1329.	0.3	9
193	Systematic identification of functionally relevant risk alleles to stratify aggressive versus indolent prostate cancer. Oncotarget, 2018, 9, 12812-12824.	0.8	8
194	Can pre-diagnostic serum levels of sodium and potassium predict prostate cancer survival?. BMC Cancer, 2018, 18, 1169.	1.1	5
195	Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices. Translational Andrology and Urology, 2018, 7, 83-97.	0.6	99
196	Occupational exposure and risk of testicular cancer: what can an ecological study in the Nordic countries tell us?. BJU International, 2018, 122, 351-351.	1.3	0
197	Longitudinal study of body mass index, dyslipidemia, hyperglycemia, and hypertension in 60,000 men and women in Sweden and Austria. PLoS ONE, 2018, 13, e0197830.	1.1	14
198	Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity. Breast Cancer Research and Treatment, 2018, 172, 167-177.	1.1	33

#	Article	IF	Citations
199	Lymph node regression and survival following neoadjuvant chemotherapy in oesophageal adenocarcinoma. British Journal of Surgery, 2018, 105, 1639-1649.	0.1	52
200	Glucose, lipids and gamma-glutamyl transferase measured before prostate cancer diagnosis and secondly diagnosed primary tumours: a prospective study in the Swedish AMORIS cohort. BMC Cancer, 2018, 18, 205.	1.1	3
201	H eterogeneity in risk of prostate cancer: A S wedish populationâ€based cohort study of competing risks and T ype 2 diabetes mellitus. International Journal of Cancer, 2018, 143, 1868-1875.	2.3	9
202	Cognitive training for technical and nonâ€technical skills in robotic surgery: a randomised controlled trial. BJU International, 2018, 122, 1075-1081.	1.3	25
203	Impact of incremental circumferential resection margin distance on overall survival and recurrence in oesophageal adenocarcinoma. BJS Open, 2018, 2, 229-237.	0.7	20
204	A case-control study of lower urinary-tract infections, associated antibiotics and the risk of developing prostate cancer using PCBaSe 3.0. PLoS ONE, 2018, 13, e0195690.	1.1	6
205	Thyroid cancer risk in the Swedish AMORIS study: the role of inflammatory biomarkers in serum. Oncotarget, 2018, 9, 774-782.	0.8	7
206	Repurposing tin mesoporphyrin as a novel immune checkpoint therapy in the treatment of cancer: A preclinical evaluation.. Journal of Clinical Oncology, 2018, 36, e15129-e15129.	0.8	0
207	Abstract A059: Lifestyle and health-related quality of life in men with metastatic prostate cancer. , 2018, , .		0
208	Abstract A057: Examining the link between obesity, inflammation, and exercise in patients with metastatic prostate cancerâ€"An interim analysis from the ExPeCT trial. , 2018, , .		0
209	Are you now a good surgeon? T2 positive margin status as a quality outcome measure following radical prostatectomy. World Journal of Urology, 2017, 35, 35-43.	1.2	12
210	Re: Adi J. Klil-Drori, Hui Yin, Vicky Tagalakis, Armen Aprikian, Laurent Azoulay. Androgen Deprivation Therapy for Prostate Cancer and Risk of Venous Thromboembolism. Eur Urol 2016;70:56â€"61. European Urology, 2017, 71, e61-e62.	0.9	0
211	CanWalk: a feasibility study with embedded randomised controlled trial pilot of a walking intervention for people with recurrent or metastatic cancer. BMJ Open, 2017, 7, e013719.	0.8	31
212	A latent class model for competing risks. Statistics in Medicine, 2017, 36, 2100-2119.	0.8	9
213	Who is at risk of death from nephrectomy? An analysis of thirtyâ€day mortality after 21 380 nephrectomies in 3 years of the British Association of Urological Surgeons (BAUS) National Nephrectomy Audit. BJU International, 2017, 120, 358-364.	1.3	16
214	Diagnostic value of MRI-based PSA density in predicting transperineal sector-guided prostate biopsy outcomes. International Urology and Nephrology, 2017, 49, 1335-1342.	0.6	12
215	Serum inflammatory markers and colorectal cancer risk and survival. British Journal of Cancer, 2017, 116, 1358-1365.	2.9	61
216	Prostate Cancer Radiation Therapy and Risk of Thromboembolic Events. International Journal of Radiation Oncology Biology Physics, 2017, 97, 1026-1031.	0.4	9

#	Article	IF	Citations
217	Cohort Profile: The AMORIS cohort. International Journal of Epidemiology, 2017, 46, 1103-1103i.	0.9	35
218	Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer. Nature Communications, 2017, 8, 420.	5.8	91
219	Gonadotropin-releasing Hormone Agonists, Orchiectomy, and Risk of Cardiovascular Disease: Semi-ecologic, Nationwide, Population-based Study. European Urology, 2017, 72, 920-928.	0.9	21
220	Atopy and prostate cancer: Is there a link between circulating levels of IgE and PSA in humans?. Cancer Immunology, Immunotherapy, 2017, 66, 1557-1562.	2.0	4
221	Toward an MRI-based nomogram for the prediction of transperineal prostate biopsy outcome: A physician and patient decision tool. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 664.e11-664.e18.	0.8	24
222	Human development and its impact on genitourinary cancers. BJU International, 2017, 120, 747-748.	1.3	0
223	Glucose and lipoprotein biomarkers and breast cancer severity using data from the Swedish AMORIS cohort. BMC Cancer, 2017, 17, 246.	1.1	12
224	Circulating gamma-glutamyl transferase and development of specific breast cancer subtypes: findings from the Apolipoprotein Mortality Risk (AMORIS) cohort. Breast Cancer Research, 2017, 19, 22.	2.2	9
225	Investigating nutrition and lifestyle factors as determinants of abdominal obesity: an environment-wide study. International Journal of Obesity, 2017, 41, 340-347.	1.6	16
226	Prospective study of Type 2 diabetes mellitus, anti-diabetic drugs and risk of prostate cancer. International Journal of Cancer, 2017, 140, 611-617.	2.3	47
227	Quantifying the Transition from Active Surveillance to Watchful Waiting Among Men with Very Low-risk Prostate Cancer. European Urology, 2017, 72, 534-541.	0.9	17
228	Preâ€diabetes and serum sex steroid hormones among <scp>US</scp> men. Andrology, 2017, 5, 49-57.	1.9	19
229	Raised preoperative international normalised ratio (INR) identifies patients at high risk of perioperative death after simultaneous renal and cardiac surgery for tumours involving the periâ€diaphragmatic inferior vena cava and right atrium. BJU International, 2017, 119, 424-429.	1.3	8
230	The ExPeCT (Examining Exercise, Prostate Cancer and Circulating Tumour Cells) trial: study protocol for a randomised controlled trial. Trials, 2017, 18, 456.	0.7	6
231	Patterns of recurrence in oesophageal cancer following oesophagectomy in the era of neoadjuvant chemotherapy. BJS Open, 2017, 1, 182-190.	0.7	18
232	Real World Evidence: A Quantitative and Qualitative Glance at Participant Feedback from a Free-Response Survey Investigating Experiences of a Structured Exercise Intervention for Men with Prostate Cancer. BioMed Research International, 2017, 2017, 1-10.	0.9	14
233	Metformin and longevity (METAL): a window of opportunity study investigating the biological effects of metformin in localised prostate cancer. BMC Cancer, 2017, 17, 494.	1.1	17
234	Kingâ€™s Health Partnersâ€™ Prostate Cancer Biobank (KHP PCaBB). BMC Cancer, 2017, 17, 784.	1.1	8

#	Article	IF	Citations
235	Circulating uric acid levels and subsequent development of cancer in 493,281 individuals: findings from the AMORIS Study. Oncotarget, 2017, 8, 42332-42342.	0.8	37
236	Serum biomarkers to predict risk of testicular and penile cancer in AMORIS. Ecancermedicalscience, 2017, 11, 762.	0.6	6
237	Your next clinical cancer research project: preparation in a. Ecancermedicalscience, 2017, 11, ed64.	0.6	1
238	Spezifische Todesursachen von Patienten mit nicht-metastasierenden Prostatakrebs. Gesundheitswesen, 2017, 79, .	0.8	0
239	Confirmatory biopsy for the assessment of prostate cancer in men considering active surveillance: reference centre experience. Ecancermedicalscience, 2016, 10, 633.	0.6	6
240	Serial transperineal sector prostate biopsies: impact on long-term erectile dysfunction. Ecancermedicalscience, 2016, 10, 643.	0.6	7
241	Research engagement among black men with prostate cancer. Ecancermedicalscience, 2016, 10, 695.	0.6	8
242	Laparoscopic radical prostatectomy outcome data: how should surgeonâ€™s performance be reported? A retrospective learning curve analysis of two surgeons. Ecancermedicalscience, 2016, 10, 651.	0.6	6
243	Serum Calcium and the Risk of Breast Cancer: Findings from the Swedish AMORIS Study and a Meta-Analysis of Prospective Studies. International Journal of Molecular Sciences, 2016, 17, 1487.	1.8	28
244	Associations of C-Reactive Protein, Granulocytes and Granulocyte-to-Lymphocyte Ratio with Mortality from Breast Cancer in Non-Institutionalized American Women. PLoS ONE, 2016, 11, e0157482.	1.1	11
245	Investigating the association between allergen-specific immunoglobulin E, cancer risk and survival. OncoImmunology, 2016, 5, e1154250.	2.1	34
246	Risk of thromboembolic disease in men with prostate cancer undergoing androgen deprivation therapy. BJU International, 2016, 118, 391-398.	1.3	23
247	Association between serum calcium concentration and risk of incident and fatal cardiovascular disease in the prospective AMORIS study. Atherosclerosis, 2016, 251, 85-93.	0.4	56
248	Is there a role for <scp>IGF</scp>â€1 in the development of second primary cancers?. Cancer Medicine, 2016, 5, 3353-3367.	1.3	57
249	Serum leptin, Câ€reactive protein, and cancer mortality in the <scp>NHANES III</scp>. Cancer Medicine, 2016, 5, 120-128.	1.3	26
250	Association between baseline serum glucose, triglycerides and total cholesterol, and prostate cancer risk categories. Cancer Medicine, 2016, 5, 1307-1318.	1.3	46
251	Interpretation of conventional survival analysis and competingâ€risk analysis: an example of hypertension and prostate cancer. BJU International, 2016, 118, 850-852.	1.3	9
252	Causes of death in men with localized prostate cancer: a nationwide, populationâ€based study. BJU International, 2016, 117, 507-514.	1.3	43

#	Article	IF	Citations
253	Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer. International Journal of Cancer, 2016, 139, 2698-2704.	2.3	29
254	Prostate-specific antigen testing in inner London general practices: are those at higher risk most likely to get tested?. BMJ Open, 2016, 6, e011356.	0.8	16
255	Cohort Profile Update: The National Prostate Cancer Register of Sweden and Prostate Cancer data Baseâ€"a refined prostate cancer trajectory. International Journal of Epidemiology, 2016, 45, 73-82.	0.9	78
256	Lamellipodin promotes invasive 3D cancer cell migration via regulated interactions with Ena/VASP and SCAR/WAVE. Oncogene, 2016, 35, 5155-5169.	2.6	76
257	Family history of breast cancer and its association with disease severity and mortality. Cancer Medicine, 2016, 5, 942-949.	1.3	24
258	Progression of breast cancer following locoregional ipsilateral recurrence: importance of interval time. British Journal of Cancer, 2016, 114, 88-95.	2.9	18
259	Determinants of non-adherence to adjuvant endocrine treatment in early stage breast cancer patients: A Swedish population-based registry linkage study.. Journal of Clinical Oncology, 2016, 34, 535-535.	0.8	0
260	How to model temporal changes in comorbidity for cancer patients using prospective cohort data. BMC Medical Informatics and Decision Making, 2015, 15, 96.	1.5	11
261	Prediagnostic serum glucose and lipids in relation to survival in breast cancer patients: a competing risk analysis. BMC Cancer, 2015, 15, 913.	1.1	22
262	Systematic review of high-intensity focused ultrasound ablation in the treatment of breast cancer. British Journal of Surgery, 2015, 102, 873-882.	0.1	70
263	An investigation into the relationship between statins and cancer using population-based data. BJU International, 2015, 116, 681-683.	1.3	5
264	Adjuvant taxanes and the development of breast cancer-related arm lymphoedema. British Journal of Surgery, 2015, 102, 1071-1078.	0.1	54
265	Comparison of three magnetic nanoparticle tracers for sentinel lymph node biopsy in an in vivo porcine model. International Journal of Nanomedicine, 2015, 10, 1235.	3.3	33
266	Metabolic serum biomarkers for the prediction of cancer: a follow-up of the studies conducted in the Swedish AMORIS study. Ecancermedicalscience, 2015, 9, 555.	0.6	7
267	The association between circulating IGF1, IGFBP3, and calcium: results from NHANES III. Endocrine Connections, 2015, 4, 187-195.	0.8	14
268	Quantifying Observational Evidence for Risk of Fatal and Nonfatal Cardiovascular Disease Following Androgen Deprivation Therapy for Prostate Cancer: A Meta-analysis. European Urology, 2015, 68, 386-396.	0.9	211
269	The Association of Milk and Dairy Consumption and Calcium Intake With the Risk and Severity of Prostate Cancer. Current Nutrition Reports, 2015, 4, 66-71.	2.1	2
270	Optimising magnetic sentinel lymph node biopsy in an in vivo porcine model. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 993-1002.	1.7	8

#	Article	IF	Citations
271	Prediagnostic serum inflammatory markers in relation to breast cancer risk, severity at diagnosis and survival in breast cancer patients. Carcinogenesis, 2015, 36, 1121-1128.	1.3	43
272	Risk and Timing of Cardiovascular Disease After Androgen-Deprivation Therapy in Men With Prostate Cancer. Journal of Clinical Oncology, 2015, 33, 1243-1251.	0.8	225
273	Serum lactate dehydrogenase and survival following cancer diagnosis. British Journal of Cancer, 2015, 113, 1389-1396.	2.9	66
274	Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanoma. OncoImmunology, 2015, 4, e1032492.	2.1	53
275	Quantifying the Evidence for the Risk of Metabolic Syndrome and Its Components following Androgen Deprivation Therapy for Prostate Cancer: A Meta-Analysis. PLoS ONE, 2015, 10, e0117344.	1.1	67
276	Incidence of Second Malignancies for Prostate Cancer. PLoS ONE, 2014, 9, e102596.	1.1	27
277	The Biology and Natural History of Prostate Cancer: A Short Introduction. Recent Results in Cancer Research, 2014, 202, 1-7.	1.8	11
278	Is there an anti-androgen withdrawal effect with enzalutamide?. Journal of Clinical Oncology, 2014, 32, 200-200.	0.8	1
279	Role of serum lipids and glucose as biomarkers of prostate cancer severity.. Journal of Clinical Oncology, 2014, 32, 5080-5080.	0.8	0
280	Risk of inâ€hospital complications after radical cystectomy for urinary bladder carcinoma: populationâ€based followâ€up study of 7608 patients. BJU International, 2013, 112, 1113-1120.	1.3	84
281	Inorganic phosphate and the risk of cancer in the Swedish AMORIS study. BMC Cancer, 2013, 13, 257.	1.1	62
282	Systematic review of radioguided versus wire-guided localization in the treatment of non-palpable breast cancers. Breast Cancer Research and Treatment, 2013, 140, 241-252.	1.1	44
283	Serum calcium and risk of gastrointestinal cancer in the Swedish AMORIS study. BMC Public Health, 2013, 13, 663.	1.2	26
284	Iron metabolism and risk of cancer in the Swedish AMORIS study. Cancer Causes and Control, 2013, 24, 1393-1402.	0.8	51
285	Thromboembolic Events Following Surgery for Prostate Cancer. European Urology, 2013, 63, 354-363.	0.9	38
286	Calcium Intake and Serum Concentration in Relation to Risk of Cardiovascular Death in NHANES III. PLoS ONE, 2013, 8, e61037.	1.1	57
287	Magnetic sentinel lymph node biopsy and localization properties of a magnetic tracer in an in vivo porcine model. Breast Cancer Research and Treatment, 2013, 141, 33-42.	1.1	18
288	Serum Lipid Profiles and Cancer Risk in the Context of Obesity: Four Meta-Analyses. Journal of Cancer Epidemiology, 2013, 2013, 1-12.	0.5	73

#	Article	IF	Citations
289	Association of serum calcium with serum sex steroid hormones in men in NHANES III. Aging Male, 2013, 16, 151-158.	0.9	4
290	Cohort Profile: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0. International Journal of Epidemiology, 2013, 42, 956-967.	0.9	194
291	Global incidence and outcome of testicular cancer. Clinical Epidemiology, 2013, 5, 417.	1.5	138
292	Serum Glucose and Fructosamine in Relation to Risk of Cancer. PLoS ONE, 2013, 8, e54944.	1.1	20
293	Mortality following Hip Fracture in Men with Prostate Cancer. PLoS ONE, 2013, 8, e74492.	1.1	21
294	Lipid Profiles and Risk of Breast and Ovarian Cancer in the Swedish AMORIS Study. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1381-1384.	1.1	72
295	Blood Pressure and Risk of Cancer Incidence and Mortality in the Metabolic Syndrome and Cancer Project. Hypertension, 2012, 59, 802-810.	1.3	210
296	Serum Lipids and the Risk of Gastrointestinal Malignancies in the Swedish AMORIS Study. Journal of Cancer Epidemiology, 2012, 2012, 1-10.	0.5	67
297	Heterocyclic Aromatic Amine [HCA] Intake and Prostate Cancer Risk: Effect Modification by Genetic Variants. Nutrition and Cancer, 2012, 64, 704-713.	0.9	18
298	Ability of a biomarker-based score to predict death from circulatory disease and cancer in NHANES III. BMC Public Health, 2012, 12, 895.	1.2	12
299	Primary cancers before and after prostate cancer diagnosis. Cancer, 2012, 118, 6207-6216.	2.0	25
300	Serum calcium and incident and fatal prostate cancer in the Swedish AMORIS study. Cancer Causes and Control, 2012, 23, 1349-1358.	0.8	21
301	Multiple Events of Fractures and Cardiovascular and Thromboembolic Disease Following Prostate Cancer Diagnosis: Results From the Population-Based PCBaSe Sweden. European Urology, 2012, 61, 690-700.	0.9	15
302	Ischemic heart disease and stroke before and during endocrine treatment for prostate cancer in PCBaSe Sweden. International Journal of Cancer, 2012, 130, 478-487.	2.3	21
303	The interplay between lipid profiles, glucose, BMI and risk of kidney cancer in the Swedish AMORIS study. International Journal of Cancer, 2012, 130, 2118-2128.	2.3	47
304	Biomarker-based score to predict mortality in persons aged 50 years and older: a new approach in the Swedish AMORIS study. International Journal of Molecular Epidemiology and Genetics, 2012, 3, 66-76.	0.4	24
305	Gamma-glutamyltransferase and risk of cancer in a cohort of 545,460 persons â€“ the Swedish AMORIS study. European Journal of Cancer, 2011, 47, 2033-2041.	1.3	83
306	Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. BJU International, 2011, 108, 1279-1283.	1.3	50

#	Article	IF	Citations
307	Low levels of apolipoprotein A-I and HDL are associated with risk of prostate cancer in the Swedish AMORIS study. Cancer Causes and Control, 2011, 22, 1011-1019.	0.8	63
308	Prostate cancer risk in the Swedish AMORIS study. Cancer, 2011, 117, 2086-2095.	2.0	87
309	Risk of prostate cancer is not associated with levels of Câ€reactive protein and other commonly used markers of inflammation. International Journal of Cancer, 2011, 129, 1485-1492.	2.3	39
310	Association between Levels of C-Reactive Protein and Leukocytes and Cancer: Three Repeated Measurements in the Swedish AMORIS Study. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 428-437.	1.1	52
311	Immunoglobulin E and cancer: a meta-analysis and a large Swedish cohort study. Cancer Causes and Control, 2010, 21, 1657-1667.	0.8	49
312	Absolute and Relative Risk of Cardiovascular Disease in Men With Prostate Cancer: Results From the Population-Based PCBaSe Sweden. Journal of Clinical Oncology, 2010, 28, 3448-3456.	0.8	173
313	Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden. Lancet Oncology, The, 2010, 11, 450-458.	5.1	110
314	Phenotyping Gamma Delta T cells in Bladder Cancer. Frontiers in Oncology, 0, 9, .	1.3	1
315	Is brachytherapy a viable treatment option for muscle-invasive bladder cancer?. Frontiers in Oncology, 0, 9, .	1.3	0
316	A pilot study to evaluate patient reported outcome measures of bladder cancer patients undergoing radical cystectomy at Guyâ€™s and St Thomasâ€™ NHS Foundation Trust.. Frontiers in Oncology, 0, 9, .	1.3	0
317	Neutrophil to lymphocyte ratio (NLR) as a predictor of outcomes in patients with urothelial carcinoma (UC) treated with immune checkpoint inhibitors (ICI). Frontiers in Oncology, 0, 9, .	1.3	0
318	Clinical outcomes of patients with squamous cell bladder cancer versus urothelial carcinoma with squamous differentiation after radical treatment. Frontiers in Oncology, 0, 9, .	1.3	0
319	Cohort Profile: Kingâ€™s Health Partners Bladder Cancer Biobank (KHP BCaBB). Frontiers in Oncology, 0, 9, .	1.3	0
320	The role of iron infusion in post-operative outcomes following radical cystectomy. Frontiers in Oncology, 0, 9, .	1.3	0
321	Serum immunoglobulin levels and the risk of bladder cancer in the AMORIS Cohort. Frontiers in Oncology, 0, 9, .	1.3	0
322	MRI-based nomogram for the prediction of prostate cancer diagnosis: A multi-centre validated patientâ€“physician decision tool. Journal of Clinical Urology, 0, , 205141582110659.	0.1	4
323	Impact of the COVIDâ€19 pandemic on urological cancers: The surgical experience of two cancer hubs in London and Milan. BJUI Compass, 0, , .	0.7	3
324	The experience of UK patients with bladder cancer during the second wave of the COVIDâ€19 pandemic. BJUI Compass, 0, , .	0.7	1

#	Article	IF	Citations
325	Radical cancer treatment is safe during COVID-19: the real-world experience of a large London-based Comprehensive Cancer Centre during the first wave. British Journal of Cancer, 0, , .	2.9	2